Chronic pain is a neurological disorder that impacts the lives of millions of Americans. Current treatments for chronic pain are limited by abuse potential and intolerable side effects. Endogenous proteases contribute to acute and chronic pain through the direct activation of the protease activated receptor-2 (PAR2) G-protein coupled receptor (GPCR). PAR2 is known to play an important role in chemical, inflammatory and cancer-induced pain but the possible efficacy of PAR2 antagonists in these preclinical models has not been assessed due to lack of available tools or clinical candidate compounds. Moreover, activation of PAR2 can lead to engagement of multiple signaling pathways yet agonists/antagonists with signaling pathway specific efficacy have not been explored as potential tools for understanding the role of PAR2 signaling in nociception. Studies assessing PAR2 activation and signaling pathway specific efficacy in the peripheral nervous system are important for the potential clinical development of PAR2 ligands for the treatment of pathological pain in humans. We are developing novel ligands to PAR2 in an effort to better elucidate the role of this receptor in nociception and to develop compounds that may have clinical utility for the treatment of pain. The central hypothesis of this application is that PAR2 plays a pivotal role in causing acute pain and promoting chronic pain and that high affinity ligands of the PAR2 receptor will represent a novel class of analgesics with utility in a number of chronic pain conditions. Thus, the primary objectives of this proposal are to develop novel and specific ligands to PAR2, to fully elucidate PAR2 contribution to acute and chronic pain, and to evaluate PAR2 ligand efficacy as novel analgesics in preclinical pain models. Successful completion of these studies will result in: 1) the discovery and development of novel agonists/antagonists for PAR2;2) determination of signaling pathways that are engaged or attenuated by these novel agonists/antagonists;and 3) in vivo validation of PAR2 as an important pharmacological target for pain treatment. From these studies we intend to gain a more complete understanding of the physiological ramifications of different modes of agonist action at PAR2 as it relates to the nociceptive system. Successful studies will provide a preclinical rationale for the further development and testing of PAR2 ligands for the treatment of pain. Such findings represent a major step forward in the development of novel ligands to treat acute/chronic pain that can result from a variety of pathologies in humans.

Public Health Relevance

Chronic pain is a frequent consequence of injury or disease and impacts the lives of millions of Americans. Available treatments for chronic pain have side effects that make them untenable in many, if not most, of these cases. We propose to develop novel analgesics with increased efficacy directed at a key player in pain sensitization, the protease activated receptor-2. Such agents will be useful in elucidating the role of the protease activated receptor-2 in chronic pain states and may represent a novel therapeutic avenue for the treatment of persistent chronic pain following injury or disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS073664-03
Application #
8543773
Study Section
Special Emphasis Panel (ZRG1-MDCN-P (91))
Program Officer
Babcock, Debra J
Project Start
2011-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$316,408
Indirect Cost
$105,314
Name
University of Arizona
Department
Physiology
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Sherwood, Cara L; Boitano, Scott (2016) Airway epithelial cell exposure to distinct e-cigarette liquid flavorings reveals toxicity thresholds and activation of CFTR by the chocolate flavoring 2,5-dimethypyrazine. Respir Res 17:57
Boitano, Scott; Hoffman, Justin; Flynn, Andrea N et al. (2015) The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo. Br J Pharmacol :
Tillu, Dipti V; Hassler, Shayne N; Burgos-Vega, Carolina C et al. (2015) Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state. Pain 156:859-67
Boitano, Scott; Hoffman, Justin; Tillu, Dipti V et al. (2014) Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering. PLoS One 9:e99140
Sherwood, Cara L; Daines, Michael O; Price, Theodore J et al. (2014) A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance. Am J Physiol Cell Physiol 307:C718-26
Sherwood, Cara L; Liguori, Andrew E; Olsen, Colin E et al. (2013) Arsenic compromises conducting airway epithelial barrier properties in primary mouse and immortalized human cell cultures. PLoS One 8:e82970
Sherwood, Cara L; Lantz, R Clark; Boitano, Scott (2013) Chronic arsenic exposure in nanomolar concentrations compromises wound response and intercellular signaling in airway epithelial cells. Toxicol Sci 132:222-34
Flynn, Andrea N; Hoffman, Justin; Tillu, Dipti V et al. (2013) Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J 27:1498-510
Hoffman, Justin; Flynn, Andrea N; Tillu, Dipti V et al. (2012) Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis. Bioconjug Chem 23:2098-104
Flynn, Andrea N; Tillu, Dipti V; Asiedu, Marina N et al. (2011) The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo. J Biol Chem 286:19076-88

Showing the most recent 10 out of 12 publications